

Notice of Allowability

Application No.

10/728,947

Applicant(s)

MOCKEL ET AL.

Examiner

Art Unit

Ganapathirama Raghu

1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 03/02/2006.
2. ☒ The allowed claim(s) is/are 24-26,28 and 31-34.
3. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
2. ☒ Certified copies of the priority documents have been received in Application No. 09/860,768.
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|---|---|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892) | 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 6. <input type="checkbox"/> Interview Summary (PTO-413),
Paper No./Mail Date _____ |
| 3. <input checked="" type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date <u>12/8/2003</u> | 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit
of Biological Material | 8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9. <input type="checkbox"/> Other _____ |

DETAILED ACTION

New claims 24-34 are pending in this application for examination.

Applicants' amendments and arguments filed on Mar. 02, 2006, have been fully considered and are deemed to be persuasive to overcome the rejections previously applied. Rejections and/or objections not reiterated from previous office action are hereby withdrawn.

Drawings

Drawings submitted in this application are accepted by the Examiner for examination purposes only.

Priority

Acknowledgment is made of applicant's claim for foreign priority under 35 U.S.C. 119(a)-(d). The certified copy has been filed in parent Application No. 09/860768, filed on 05/21/2001.

EXAMINER'S AMENDMENT

An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it must be submitted no later than the payment of the issue fee.

Authorization for this Examiner's amendment was given in a telephone interview with Dr. Thomas A. Cawley (Reg. No. 40944) on 03/23/2006.

The application has been amended as follows:

Art Unit: 1652

In the claims:

Cancel claims 1-23, 27, 29, 30.

In claim 24,

Line 3, replace the phrase “a polynucleotide sequence SEQ ID NO: 1” with “the polynucleotide sequence of SEQ ID NO: 1”.

Line 5, replace the phrase “encoding a polypeptide sequence SEQ ID NO: 2” with “encoding the polypeptide sequence of SEQ ID NO: 2”.

Line 7, replace the phrase “a nucleotide sequence complementary to (a) or (b)” with “a polynucleotide sequence fully complementary to (a) or (b)”.

In claim 25,

Line 3, insert the phrase “wherein said polynucleotide encodes a polypeptide sequence with enolase activity” after the term “codon”.

In claim 28,

Line 1, delete the term “nucleotides” and replace with the phrase “a nucleotide sequence”.

In claim 31,

Line 3, replace “a polynucleotide SEQ ID NO: 3” with “the polynucleotide sequence of SEQ ID NO: 3”.

Line 4, replace the phrase “encoding a polypeptide” with “encoding the polypeptide”

Art Unit: 1652

Line 5, replace the phrase “sequence SEQ ID NO: 4” with “sequence of SEQ ID NO: 4”.

Line 6, replace the phrase “a polynucleotide sequence complementary to (a) or (b)” with “a polynucleotide sequence fully complementary to (a) or (b)”.

In claim 34,

Line 1, delete the term “comprising” and replace with “transformed with”.

Allowable Subject Matter

Claims 24-26, 28, 31-34 are allowed.

The following is an examiner’s statement of reasons for allowance: Following a diligent search it was determined that the prior art neither teaches nor suggests an isolated polynucleotide with SEQ ID NO: 1 encoding the polypeptide with SEQ ID NO: 2 and an isolated polynucleotide with SEQ ID NO: 3 encoding the polypeptide with SEQ ID NO: 4 as claimed in claims 24-26, 28, 31-34.

Any comments considered necessary by applicant must be submitted no later than the payment of issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance”.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ganapathirama Raghu whose telephone number is 571-272-4533.

Art Unit: 1652

The examiner can normally be reached on 8 am to 4.30 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300 for regular communications and for After Final communications. Any inquiry of a general nature or relating to the status of the application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

Ganapathirama Raghu, Ph.D.
Patent Examiner
Art Unit 1652

March 23, 2006.



PONNATHAPU ACHUTAMURTHY
SUPERVISORY PATENT EXAMINER
TECHNOLOGY OFFICES 1600